{"id":"W4247765498","doi":"10.1200/jco.2017.35.15_suppl.tps1107","title":"A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Rash; Taxane; Oncology; Placebo; Adverse effect; Trastuzumab; Pertuzumab; Population; Gastroenterology; Cancer; Breast cancer; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002769079,0.001913808,0.004668288,0.000575592,0.0006153827,0.00111449,0.001207171,0.002315839,0.006900076],"category_scores_gemma":[0.002694261,0.0008883435,0.001787683,0.000579269,0.001617442,0.001285594,0.0004398773,0.003209523,0.001231622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008901079,"about_ca_system_score_gemma":0.001576838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001145734,"about_ca_topic_score_gemma":0.002324911,"domain_scores_codex":[0.9987732,0.0006682277,0.00008454589,0.0002493612,0.00008169593,0.0001429844],"domain_scores_gemma":[0.9984226,0.000512382,0.0003419811,0.0001337444,0.0001453278,0.0004439399],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9877092,0.005888573,0.0001498991,0.0003370555,0.0003697778,0.00001456747,0.00002161695,0.00007537124,0.0009905035,0.00003211552,0.0002120138,0.004199329],"study_design_scores_gemma":[0.9323995,0.06609486,0.0005821405,0.00001658295,0.0002616208,0.00001098305,0.00001013394,0.0001853509,0.0001396408,0.00005127705,0.0002398063,0.000008080537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736168,0.006135664,0.001285895,0.0006417979,0.001412307,0.0126449,0.001472904,0.0002068525,0.00258293],"genre_scores_gemma":[0.9780694,0.002686922,0.002130807,0.001178871,0.0007594243,0.01104069,0.0008431247,0.00002853927,0.00326226],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006900076,"threshold_uncertainty_score":0.02308303,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07203960633910661,"score_gpt":0.4295408083241917,"score_spread":0.3575012019850851,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}